We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Virtual Asthma Clinic (VAC)

This study has been terminated.
(Poor recruitment.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00562081
First Posted: November 21, 2007
Last Update Posted: May 2, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
ASTHMA C Project
AstraZeneca
GlaxoSmithKline
Information provided by:
University of Alberta
  Purpose

Patients with asthma can be effectively treated using an Internet-based management system as demonstrated by:

  1. Physician utilization (emergency department visits and unscheduled physician visits).
  2. Health-related quality of life scores.
  3. Global health care costs.
  4. Frequency of severe exacerbations and time to first exacerbation.
  5. Asthma control days.
  6. Patient education.

Effective patient education will be associated with decreased markers of inflammation and improved indices of airways function.


Condition Intervention Phase
Asthma Behavioral: Education Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Evaluation of an Internet-based Approach to Long-term Treatment of Asthma.

Further study details as provided by University of Alberta:

Primary Outcome Measures:
  • Emergency department visits and unscheduled physician visits [ Time Frame: One year. ]
  • Good asthma control days [ Time Frame: One year. ]
  • Time to first severe exacerbation [ Time Frame: One year. ]

Secondary Outcome Measures:
  • Morning peak expiratory flow [ Time Frame: One year. ]
  • Percentage of days with symptoms [ Time Frame: One year. ]
  • Percentage of nights with asthma awakenings [ Time Frame: One year. ]
  • Number of rescue inhalations per week [ Time Frame: One year. ]
  • Health related quality of life scores [ Time Frame: One year. ]
  • Markers of inflammation: Airway hyperreactivity, Urine metabolic activity [ Time Frame: One year. ]
  • Health economic assessment: Frequency of direct health care provider contacts, Medications, Travel costs associated with medical care, Over the counter medications e. Internet/computer costs [ Time Frame: One year. ]

Enrollment: 27
Study Start Date: March 2005
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Patient does not have 24/7 access to a Certified Asthma Educator.
Behavioral: Education
Patient does not have 24/7 access to a Certified Asthma Educator.
Active Comparator: 2
Patient has 24/7 access to a Certified Asthma Educator.
Behavioral: Education
24/7 access to a Certified Asthma Educator

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Physician diagnosis of asthma at the time of enrolment.
  2. The forced expiratory volume in one second (FEV1) at base line will be at least 50 percent of the predicted value.
  3. Evidence of at least 12% increase in FEV1 following inhaled bronchodilator or airway hyperreactivity as defined by a standard methacholine challenge study.

Exclusion Criteria:

  1. Concurrent disease likely to require regular physician contact (e.g. congestive heart failure).
  2. A separate diagnosis or other pulmonary disease (e.g. pulmonary fibrosis or chronic bronchitis).
  3. An inability to access the Internet on a regular basis.
  4. Inability or unwillingness to give informed consent or to complete online health related quality of life questionnaires.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00562081


Locations
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Sponsors and Collaborators
University of Alberta
ASTHMA C Project
AstraZeneca
GlaxoSmithKline
Investigators
Principal Investigator: Irvin Mayers, MD, FRCPC University of Alberta
  More Information

ClinicalTrials.gov Identifier: NCT00562081     History of Changes
Other Study ID Numbers: M-2394
First Submitted: November 20, 2007
First Posted: November 21, 2007
Last Update Posted: May 2, 2016
Last Verified: January 2009

Keywords provided by University of Alberta:
asthma
Virtual Asthma Clinic
metabolites
asthma education

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases